Announcement on Final Clarification and Retest Result of the Third Party Testing Report on 30th July
Dear Customers:
First of all, we must respond positively to the test report issued by Janoshik Laboratories on 30 July. The report states that our Tirzepatide product is actually Semaglutide and underdosed, a result that is completely inconsistent with our own strict quality control and has caused a crisis of confidence in the community.
https://janoshik.com/tests/72643-T30_NFWFPSYUPGUL
Ingredient: Semaglutide
Purity: 99.500%, 99.5565%, 99.522%
Content: 1.96mg, 2.05mg, 2.13mg
Over the past nearly a month, we have endured many questions and pressures with our supportive customers. We are well aware that any words pale before a single test report. Therefore, in pursuit of absolute fairness and transparency, we have made a difficult but necessary decision: to send samples to three authoritative testing organisations, anonymously, by clients, through different methods of payment, and through different postal addresses, with all the costs ultimately borne by us.
We chose this approach to ensure the randomness of the samples, the independence of the submission process and the indisputability of the results, eliminating any possible challenge. We would like to thank each and every one of our clients who have assisted us with their samples and given us their trust and time during this period. We are aware of the extra pressure you have been under.
Today, we are pleased to announce the final results of our three-way review:
1. Testing organisation I: [Peptide Test]
Ingredient: Tirzepatide
Purity: 99.949%
Content: 36.603mg
2. Testing organisation II: [Janoshik]
https://janoshik.com/tests/75570-Unnamed_Sample_S1WPS895HN86
Ingredient: Tirzepatide
Purity: 99.878%
Content: 34.59mg
3. Testing organisation III: [Chromate]
https://chromate.org/verify?c=27070_R2LHB3M8M8U2
Ingredient: Tirzepatide
Purity: 99.708%
Content: 34.71mg
The conclusion is clear and consistent: not only is our product highly pure Tirzepatide, but there is definite overfilling. This result completely overturned the single previously questionable report.
In particular, it should be noted that the report that initially triggered the challenge also came from the reputable Janoshik Laboratories. We are deeply perplexed by the stark difference between the two reports. We do not intend to question the professionalism and authority of any organization, but the objective fact is that the results of the three retests from different organizations are highly consistent and fundamentally contradictory to the initial report.
Regarding the possibility of such discrepancies, we make the following rational speculations based on facts for your judgement:
1. very small probability of sample mix-up or contamination: was there any technical risk of sample mislabelling or cross-contamination during the first testing process?
2. untraceable abnormalities in transport or storage conditions: did the samples sent to the first testing organisation experience extreme conditions (e.g. high temperatures) during transport, leading to degradation of components?
3. Individual differences in testing personnel: despite the strict standards of the authority, is it possible that different operators may introduce rare errors?
Regardless of the reasons, the core fact remains: with three retests, we now have an overwhelming and repeatable chain of evidence that the batch is not faulty. Our response mechanism - that is, inviting customer-led, anonymous multiple validations - has successfully ruled out any single source of uncertainty, and this is the highest level of assurance we can give you.
A heartfelt thank you to those clients who chose to trust me despite the storm and assisted me in completing the delivery. I could not have completed this self-certification without your help. A special thank you for the stress you endured during this process.
Dear Customers:
First of all, we must respond positively to the test report issued by Janoshik Laboratories on 30 July. The report states that our Tirzepatide product is actually Semaglutide and underdosed, a result that is completely inconsistent with our own strict quality control and has caused a crisis of confidence in the community.
https://janoshik.com/tests/72643-T30_NFWFPSYUPGUL
Ingredient: Semaglutide
Purity: 99.500%, 99.5565%, 99.522%
Content: 1.96mg, 2.05mg, 2.13mg
Over the past nearly a month, we have endured many questions and pressures with our supportive customers. We are well aware that any words pale before a single test report. Therefore, in pursuit of absolute fairness and transparency, we have made a difficult but necessary decision: to send samples to three authoritative testing organisations, anonymously, by clients, through different methods of payment, and through different postal addresses, with all the costs ultimately borne by us.
We chose this approach to ensure the randomness of the samples, the independence of the submission process and the indisputability of the results, eliminating any possible challenge. We would like to thank each and every one of our clients who have assisted us with their samples and given us their trust and time during this period. We are aware of the extra pressure you have been under.
Today, we are pleased to announce the final results of our three-way review:
1. Testing organisation I: [Peptide Test]
Ingredient: Tirzepatide
Purity: 99.949%
Content: 36.603mg
2. Testing organisation II: [Janoshik]
https://janoshik.com/tests/75570-Unnamed_Sample_S1WPS895HN86
Ingredient: Tirzepatide
Purity: 99.878%
Content: 34.59mg
3. Testing organisation III: [Chromate]
https://chromate.org/verify?c=27070_R2LHB3M8M8U2
Ingredient: Tirzepatide
Purity: 99.708%
Content: 34.71mg
The conclusion is clear and consistent: not only is our product highly pure Tirzepatide, but there is definite overfilling. This result completely overturned the single previously questionable report.
In particular, it should be noted that the report that initially triggered the challenge also came from the reputable Janoshik Laboratories. We are deeply perplexed by the stark difference between the two reports. We do not intend to question the professionalism and authority of any organization, but the objective fact is that the results of the three retests from different organizations are highly consistent and fundamentally contradictory to the initial report.
Regarding the possibility of such discrepancies, we make the following rational speculations based on facts for your judgement:
1. very small probability of sample mix-up or contamination: was there any technical risk of sample mislabelling or cross-contamination during the first testing process?
2. untraceable abnormalities in transport or storage conditions: did the samples sent to the first testing organisation experience extreme conditions (e.g. high temperatures) during transport, leading to degradation of components?
3. Individual differences in testing personnel: despite the strict standards of the authority, is it possible that different operators may introduce rare errors?
Regardless of the reasons, the core fact remains: with three retests, we now have an overwhelming and repeatable chain of evidence that the batch is not faulty. Our response mechanism - that is, inviting customer-led, anonymous multiple validations - has successfully ruled out any single source of uncertainty, and this is the highest level of assurance we can give you.
A heartfelt thank you to those clients who chose to trust me despite the storm and assisted me in completing the delivery. I could not have completed this self-certification without your help. A special thank you for the stress you endured during this process.
